Paul Dent - Publications

Affiliations: 
Biochemistry Virginia Commonwealth University, Richmond, VA, United States 
Area:
Biochemistry, Cell Biology

253 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Booth L, Poklepovic A, Dent P. Not the comfy chair! Cancer drugs that act against multiple active sites. Expert Opinion On Therapeutic Targets. PMID 31709855 DOI: 10.1080/14728222.2019.1691526  0.52
2019 Booth LA, Roberts JL, Dent P. The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib. Seminars in Cancer Biology. PMID 31644944 DOI: 10.1016/j.semcancer.2019.10.013  0.52
2019 Dent P, Booth L, Poklepovic A, Hancock JF. Signaling alterations caused by drugs and autophagy. Cellular Signalling. 109416. PMID 31520735 DOI: 10.1016/j.cellsig.2019.109416  0.52
2019 Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody . Oncotarget. 10: 5120-5122. PMID 31489122 DOI: 10.18632/oncotarget.27162  0.52
2019 Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs. Molecular Cancer Therapeutics. 18: 1669. PMID 31481480 DOI: 10.1158/1535-7163.MCT-19-0666  0.52
2019 Booth L, Roberts JL, Poklepovic A, Dent P. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib. Frontiers in Oncology. 9: 650. PMID 31380285 DOI: 10.3389/fonc.2019.00650  0.52
2019 Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. PMID 31253872 DOI: 10.1038/s41388-019-0849-8  0.52
2019 Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells and . Molecular Cancer Therapeutics. 18: 1180. PMID 31160510 DOI: 10.1158/1535-7163.MCT-19-0470  0.52
2019 Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells and . Molecular Cancer Therapeutics. 18: 1179. PMID 31160509 DOI: 10.1158/1535-7163.MCT-19-0469  0.52
2019 Dasmahapatra G, Nguyen TK, Dent P, Grant S. Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]. Leukemia Research. PMID 31079870 DOI: 10.1016/j.leukres.2019.03.002  0.52
2018 Booth L, Roberts JL, Poklepovic A, Dent P. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells. Oncology Signaling. 1: 19-30. PMID 30740589 DOI: 10.1016/j.onsig.2017.07.001  0.52
2018 Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, Hancock JF, Poklepovic A, Dent P. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα and Gα and kill uveal melanoma cells. Cancer Biology & Therapy. 1-11. PMID 30571927 DOI: 10.1080/15384047.2018.1551747  0.52
2018 Booth L, Roberts JL, Spiegel S, Poklepovic A, Dent P. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition. Cancer Biology & Therapy. 1-11. PMID 30388910 DOI: 10.1080/15384047.2018.1538616  0.52
2018 Booth L, Roberts JL, Rais R, Cutler RE, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P. Neratinib augments the lethality of [regorafenib + sildenafil]. Journal of Cellular Physiology. PMID 30203445 DOI: 10.1002/jcp.27276  0.52
2018 Booth L, Roberts JL, Rais R, Cutler RE, Diala I, Lalani AS, Poklepovic A, Dent P. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. Cancer Biology & Therapy. 1-12. PMID 30183517 DOI: 10.1080/15384047.2018.1507665  0.52
2018 Booth L, Roberts JL, Poklepovic A, Dent P. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. Cancer Biology & Therapy. 1-13. PMID 30142009 DOI: 10.1080/15384047.2018.1507258  0.52
2018 Booth L, Roberts J, Poklepovic A, Dent P. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. Cancer Biology & Therapy. 1-11. PMID 30024813 DOI: 10.1080/15384047.2018.1472189  0.52
2018 Booth L, Roberts JL, Rais R, Poklepovic A, Dent P. Valproate augments Niraparib killing of tumor cells. Cancer Biology & Therapy. PMID 29923797 DOI: 10.1080/15384047.2018.1472190  0.52
2018 Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. Oncotarget. 9: 6062-6074. PMID 29464055 DOI: 10.18632/oncotarget.23681  0.52
2018 Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P. Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells. Advances in Cancer Research. 137: 1-15. PMID 29405973 DOI: 10.1016/bs.acr.2017.11.004  0.52
2018 Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. Cancer Biology & Therapy. 0. PMID 29405820 DOI: 10.1080/15384047.2018.1436024  0.52
2018 Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, Milstien S, Booth L, Spiegel S. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. Autophagy. 1-50. PMID 29368980 DOI: 10.1080/15548627.2018.1429875  0.44
2018 Booth L, Roberts JL, Avogadri-Connors F, CutlerJr RE, Lalani AS, Poklepovic A, Dent P. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biology & Therapy. 0. PMID 29333953 DOI: 10.1080/15384047.2018.1423927  0.52
2017 Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biology & Therapy. 1-6. PMID 29219657 DOI: 10.1080/15384047.2017.1394556  0.52
2017 Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget. 8: 90262-90277. PMID 29163826 DOI: 10.18632/oncotarget.21660  0.52
2017 Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget. 8: 83155-83170. PMID 29137331 DOI: 10.18632/oncotarget.17950  0.52
2017 Booth L, Roberts JL, Poklepovic A, Dent P. [pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells. Cancer Biology & Therapy. 0. PMID 28812434 DOI: 10.1080/15384047.2017.1362511  0.52
2017 Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget. PMID 28575876 DOI: 10.18632/oncotarget.17950  0.52
2017 Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. PMID 28146421 DOI: 10.18632/oncotarget.14829  0.52
2017 Booth L, Roberts JL, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget. PMID 28088782 DOI: 10.18632/oncotarget.14562  0.52
2016 Booth L, Roberts JL, Ecroyd H, Reid SP, Proniuk S, Zukiwski A, Jacob A, Damonte E, Tuñón MJ, Dent P. AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins. Journal of Clinical & Cellular Immunology. 7. PMID 27957385 DOI: 10.4172/2155-9899.1000454  0.44
2016 Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget. PMID 27903966 DOI: 10.18632/oncotarget.13640  0.52
2016 Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 291: 20823. PMID 27664064 DOI: 10.1074/jbc.A116.803444  0.52
2016 Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 291: 17535. PMID 27543593 DOI: 10.1074/jbc.A109.095208  0.52
2016 Shapiro BA, Vu NT, Shultz MD, Shultz JC, Mietla JA, Gouda MM, Yacoub A, Dent P, Fisher PB, Park MA, Chalfant CE. Melanoma differentiation associated gene 7/IL-24 exerts cytotoxic effects by altering the alternative splicing of Bcl-x pre-mRNA via the SRC/PKCδ signaling axis. The Journal of Biological Chemistry. PMID 27519412 DOI: 10.1074/jbc.M116.737569  0.52
2016 Booth L, Malkin M, Dent P. Repurposing Tecfidera for cancer. Aging. PMID 27429364  0.44
2016 Tavallai M, Booth L, Roberts JL, Poklepovic A, Dent P. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. Frontiers in Oncology. 6: 142. PMID 27379204 DOI: 10.3389/fonc.2016.00142  0.52
2016 Booth L, Albers T, Roberts JL, Tavallai M, Poklepovic A, Lebedyeva IO, Dent P. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. Oncotarget. PMID 27259258 DOI: 10.18632/oncotarget.9752  0.52
2016 Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, ... ... Dent P, et al. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget. PMID 27213589 DOI: 10.18632/oncotarget.9434  0.52
2016 Booth L, Roberts JL, Ecroyd H, Tritsch SR, Bavari S, Reid SP, Proniuk S, Zukiwski A, Jacob A, Sepúlveda CS, Giovannoni F, García CC, Damonte E, González-Gallego J, Tuñón MJ, ... Dent P, et al. AR-12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication. Journal of Cellular Physiology. PMID 27187154 DOI: 10.1002/jcp.25431  0.52
2016 Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget. PMID 27015562 DOI: 10.18632/oncotarget.8281  0.52
2016 Tavallai M, Booth L, Roberts JL, McGuire WP, Poklepovic A, Dent P. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. Oncotarget. PMID 26981780 DOI: 10.18632/oncotarget.8039  0.52
2016 Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. PMID 26934000 DOI: 10.18632/oncotarget.7746  0.52
2016 Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. PMID 26887051 DOI: 10.18632/oncotarget.7349  0.52
2015 Das A, Durrant D, Mitchell C, Dent P, Batra SK, Kukreja RC. Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. Oncotarget. PMID 26716643 DOI: 10.18632/oncotarget.6749  0.48
2015 Webb T, Carter J, Roberts JL, Poklepovic A, McGuire WP, Booth L, Dent P. Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. Cancer Biology & Therapy. 1-11. PMID 26417912 DOI: 10.1080/15384047.2015.1099769  0.52
2015 Nahta R, Al-Mulla F, Al-Temaimi R, Amedei A, Andrade-Vieira R, Bay S, G Brown D, Calaf GM, Castellino RC, Cohen-Solal KA, Colacci A, Cruickshanks N, Dent P, Di Fiore R, Forte S, et al. Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis. 36: S2-S18. PMID 26106139 DOI: 10.1093/carcin/bgv028  0.52
2015 Durrant DE, Das A, Dyer S, Tavallai S, Dent P, Kukreja RC. Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. Molecular Pharmacology. 88: 512-23. PMID 26101222 DOI: 10.1124/mol.115.099143  0.52
2015 Roberts JL, Tavallai M, Nourbakhsh A, Fidanza A, Cruz-Luna T, Smith E, Siembida P, Plamondon P, Cycon KA, Doern CD, Booth L, Dent P. GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. Journal of Cellular Physiology. 230: 2552-78. PMID 25858032 DOI: 10.1002/jcp.25014  0.52
2015 Cruickshanks N, Roberts JL, Bareford MD, Tavallai M, Poklepovic A, Booth L, Spiegel S, Dent P. Differential regulation of autophagy and cell viability by ceramide species. Cancer Biology & Therapy. 16: 733-42. PMID 25803131 DOI: 10.1080/15384047.2015.1026509  0.52
2015 Booth L, Roberts JL, Tavallai M, Nourbakhsh A, Chuckalovcak J, Carter J, Poklepovic A, Dent P. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. Journal of Cellular Physiology. 230: 1982-98. PMID 25736380 DOI: 10.1002/jcp.24977  0.52
2015 Tavallai M, Hamed HA, Roberts JL, Cruickshanks N, Chuckalovcak J, Poklepovic A, Booth L, Dent P. Nexavar/Stivarga and viagra interact to kill tumor cells. Journal of Cellular Physiology. 230: 2281-98. PMID 25704960 DOI: 10.1002/jcp.24961  0.52
2015 Booth L, Roberts JL, Dent P. HSPA5/Dna K may be a useful target for human disease therapies. Dna and Cell Biology. 34: 153-8. PMID 25689303 DOI: 10.1089/dna.2015.2808  0.52
2015 Booth L, Roberts JL, Cash DR, Tavallai S, Jean S, Fidanza A, Cruz-Luna T, Siembiba P, Cycon KA, Cornelissen CN, Dent P. GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. Journal of Cellular Physiology. 230: 1661-76. PMID 25546329 DOI: 10.1002/jcp.24919  0.52
2015 Sarkar S, Quinn BA, Shen X, Dent P, Das SK, Emdad L, Sarkar D, Fisher PB. Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approach. Molecular Pharmacology. 87: 286-95. PMID 25452327 DOI: 10.1124/mol.114.094375  0.52
2015 Gurbuz N, Park MA, Dent P, Abdel Mageed AB, Sikka SC, Baykal A. Cystine dimethyl ester induces apoptosis through regulation of PKC-δ and PKC-ε in prostate cancer cells. Anti-Cancer Agents in Medicinal Chemistry. 15: 217-27. PMID 25410184  0.36
2015 Booth L, Roberts JL, Cruickshanks N, Tavallai S, Webb T, Samuel P, Conley A, Binion B, Young HF, Poklepovic A, Spiegel S, Dent P. PDE5 inhibitors enhance celecoxib killing in multiple tumor types. Journal of Cellular Physiology. 230: 1115-27. PMID 25303541 DOI: 10.1002/jcp.24843  0.52
2015 Hamed HA, Tavallai S, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of Cellular Physiology. 230: 131-9. PMID 24911215 DOI: 10.1002/jcp.24689  0.52
2014 Booth L, Cruickshanks N, Tavallai S, Roberts JL, Peery M, Poklepovic A, Dent P. Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Cancer Biology & Therapy. 15: 1646-57. PMID 25482938 DOI: 10.4161/15384047.2014.967992  0.52
2014 Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. Molecular Cancer Therapeutics. 13: 2384-98. PMID 25103559 DOI: 10.1158/1535-7163.MCT-14-0172  0.52
2014 Menezes ME, Bhatia S, Bhoopathi P, Das SK, Emdad L, Dasgupta S, Dent P, Wang XY, Sarkar D, Fisher PB. MDA-7/IL-24: multifunctional cancer killing cytokine. Advances in Experimental Medicine and Biology. 818: 127-53. PMID 25001534 DOI: 10.1007/978-1-4471-6458-6_6  0.52
2014 Roberts JL, Booth L, Conley A, Cruickshanks N, Malkin M, Kukreja RC, Grant S, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biology & Therapy. 15: 758-67. PMID 24651037 DOI: 10.4161/cbt.28553  0.52
2014 Dent P. Met in lung cancer. Cancer Biology & Therapy. 15: 653-4. PMID 24618893 DOI: 10.4161/cbt.28504  0.52
2014 Dent P. New methods to control neuroblastoma growth. Cancer Biology & Therapy. 15: 481-2. PMID 24618834 DOI: 10.4161/cbt.28465  0.52
2014 Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biology & Therapy. 15: 578-85. PMID 24556916 DOI: 10.4161/cbt.28163  0.52
2014 Bhatia S, Emdad L, Das SK, Hamed H, Dent P, Sarkar D, Fisher PB. Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. Expert Opinion On Investigational Drugs. 23: 489-500. PMID 24502370 DOI: 10.1517/13543784.2014.884558  0.52
2014 Dent P. Not so WEE: targeting G₂/M to kill mesothelioma cells. Cancer Biology & Therapy. 15: 351-2. PMID 24496096 DOI: 10.4161/cbt.27851  0.52
2014 Dent P. Crosstalk between ERK, AKT, and cell survival. Cancer Biology & Therapy. 15: 245-6. PMID 24424114 DOI: 10.4161/cbt.27541  0.52
2014 Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biology & Therapy. 15: 380-8. PMID 24365782 DOI: 10.4161/cbt.27623  0.52
2014 Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Molecular Pharmacology. 85: 408-19. PMID 24353313 DOI: 10.1124/mol.113.090043  0.52
2014 Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biology & Therapy. 15: 305-16. PMID 24351423 DOI: 10.4161/cbt.27309  0.52
2014 Dent P. Multi-kinase inhibition in ovarian cancer. Cancer Biology & Therapy. 15: 1-2. PMID 24309512 DOI: 10.4161/cbt.26708  0.52
2014 Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cellular Signalling. 26: 549-55. PMID 24308968 DOI: 10.1016/j.cellsig.2013.11.028  0.52
2014 Kegelman TP, Das SK, Hu B, Bacolod MD, Fuller CE, Menezes ME, Emdad L, Dasgupta S, Baldwin AS, Bruce JN, Dent P, Pellecchia M, Sarkar D, Fisher PB. MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro-Oncology. 16: 50-61. PMID 24305713 DOI: 10.1093/neuonc/not157  0.52
2014 Azab BM, Dash R, Das SK, Bhutia SK, Sarkar S, Shen XN, Quinn BA, Dent P, Dmitriev IP, Wang XY, Curiel DT, Pellecchia M, Reed JC, Sarkar D, Fisher PB. Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV). Journal of Cellular Physiology. 229: 34-43. PMID 23868767 DOI: 10.1002/jcp.24408  0.52
2013 Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB, Dent P. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biology & Therapy. 14: 1039-49. PMID 24025359 DOI: 10.4161/cbt.26110  0.52
2013 Dent P. ERK plays the baddie (again). Cancer Biology & Therapy. 14: 997-8. PMID 24025356 DOI: 10.4161/cbt.26377  0.52
2013 Dent P. Arsenic in leukemia: a RSKy business. Cancer Biology & Therapy. 14: 871-2. PMID 24025257 DOI: 10.4161/cbt.26159  0.52
2013 Dent P. PARP inhibitors are not all equal. Cancer Biology & Therapy. 14: 873-4. PMID 24025256 DOI: 10.4161/cbt.26160  0.52
2013 Dent P. Janus-faced Kupffer cells in tumor metastasis. Cancer Biology & Therapy. 14: 875-6. PMID 24025255 DOI: 10.4161/cbt.26161  0.52
2013 Dent P. Non-canonical p53 signaling to promote invasion. Cancer Biology & Therapy. 14: 879-80. PMID 24025254 DOI: 10.4161/cbt.26174  0.52
2013 Dent P. Multi-kinase modulation for colon cancer therapy. Cancer Biology & Therapy. 14: 877-8. PMID 24025253 DOI: 10.4161/cbt.26176  0.52
2013 Dent P. Ceramide in the prostate. Cancer Biology & Therapy. 14: 881-2. PMID 24025252 DOI: 10.4161/cbt.26212  0.52
2013 Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biology & Therapy. 14: 982-96. PMID 24025251 DOI: 10.4161/cbt.26234  0.52
2013 Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, Derecka M, Chen Q, Hu Y, Sisler J, Hamed H, Lesnefsky EJ, Valerie K, Dent P, Larner AC. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. The Journal of Biological Chemistry. 288: 31280-8. PMID 24019511 DOI: 10.1074/jbc.M113.505057  0.48
2013 Dent P. FADD the bad in head and neck cancer. Cancer Biology & Therapy. 14: 780-1. PMID 23974629 DOI: 10.4161/cbt.26151  0.52
2013 Dent P. The multi-hit hypothesis in basal-like breast cancer. Cancer Biology & Therapy. 14: 778-9. PMID 23974512 DOI: 10.4161/cbt.26140  0.52
2013 Dent P. HDACIs and the inhibition of invasive potential. Cancer Biology & Therapy. 14: 776-7. PMID 23974427 DOI: 10.4161/cbt.26139  0.52
2013 Dent P. The flip side of doxorubicin: Inflammatory and tumor promoting cytokines. Cancer Biology & Therapy. 14: 774-5. PMID 23974349 DOI: 10.4161/cbt.26125  0.52
2013 Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biology & Therapy. 14: 458-65. PMID 23917378 DOI: 10.4161/cbt.24424  0.52
2013 Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Molecular Pharmacology. 84: 562-71. PMID 23877009 DOI: 10.1124/mol.113.088005  0.52
2013 Bhutia SK, Mukhopadhyay S, Sinha N, Das DN, Panda PK, Patra SK, Maiti TK, Mandal M, Dent P, Wang XY, Das SK, Sarkar D, Fisher PB. Autophagy: cancer's friend or foe? Advances in Cancer Research. 118: 61-95. PMID 23768510 DOI: 10.1016/B978-0-12-407173-5.00003-0  0.52
2013 Bhutia SK, Das SK, Azab B, Menezes ME, Dent P, Wang XY, Sarkar D, Fisher PB. Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. International Journal of Cancer. Journal International Du Cancer. 133: 2726-36. PMID 23720015 DOI: 10.1002/ijc.28289  0.52
2013 Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. Journal of Cellular Physiology. 228: 1996-2005. PMID 23674352 DOI: 10.1002/jcp.24362  0.52
2013 Hamed HA, Yacoub A, Park MA, Archer K, Das SK, Sarkar D, Grant S, Fisher PB, Dent P. Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells. Molecular Pharmacology. 84: 171-81. PMID 23661648 DOI: 10.1124/mol.113.086553  0.52
2013 Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British Journal of Haematology. 161: 43-56. PMID 23360303 DOI: 10.1111/bjh.12206  0.52
2013 Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher PB. MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Research. 73: 844-54. PMID 23233738 DOI: 10.1158/0008-5472.CAN-12-1681  0.52
2013 Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Targeting the Bcl-2 family for cancer therapy. Expert Opinion On Therapeutic Targets. 17: 61-75. PMID 23173842 DOI: 10.1517/14728222.2013.733001  0.52
2012 Das SK, Sarkar S, Dash R, Dent P, Wang XY, Sarkar D, Fisher PB. Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes. Advances in Cancer Research. 115: 1-38. PMID 23021240 DOI: 10.1016/B978-0-12-398342-8.00001-X  0.52
2012 Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biology & Therapy. 13: 1501-11. PMID 22990204 DOI: 10.4161/cbt.22275  0.52
2012 Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Molecular Pharmacology. 82: 1217-29. PMID 22989520 DOI: 10.1124/mol.112.081539  0.52
2012 Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Molecular Pharmacology. 82: 1030-41. PMID 22923501 DOI: 10.1124/mol.112.079624  0.52
2012 Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Research. 72: 4225-37. PMID 22693249 DOI: 10.1158/0008-5472.CAN-12-1118  0.52
2012 Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biology & Therapy. 13: 793-803. PMID 22673740 DOI: 10.4161/cbt.20562  0.52
2012 Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Molecular Pharmacology. 82: 322-32. PMID 22596349 DOI: 10.1124/mol.112.078907  0.52
2012 Emdad L, Dent P, Sarkar D, Fisher PB. Future approaches for the therapy of malignant glioma: targeting genes mediating invasion. Future Oncology (London, England). 8: 343-6. PMID 22515436 DOI: 10.2217/fon.12.16  0.52
2012 Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Molecular Cancer Therapeutics. 11: 1122-32. PMID 22411899 DOI: 10.1158/1535-7163.MCT-12-0021  0.52
2012 Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biology & Therapy. 13: 567-74. PMID 22406992 DOI: 10.4161/cbt.19771  0.52
2012 Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular Pharmacology. 81: 748-58. PMID 22357666 DOI: 10.1124/mol.112.077586  0.52
2012 Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biology & Therapy. 13: 224-36. PMID 22354011 DOI: 10.4161/cbt.13.4.18877  0.52
2012 Tang Y, Dai Y, Grant S, Dent P. Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biology & Therapy. 13: 379-88. PMID 22313687 DOI: 10.4161/cbt.19240  0.52
2012 Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular Pharmacology. 81: 527-40. PMID 22219388 DOI: 10.1124/mol.111.076851  0.52
2012 Rosato R, Hock S, Dent P, Dai Y, Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leukemia Research. 36: 491-8. PMID 22074700 DOI: 10.1016/j.leukres.2011.10.020  0.52
2012 Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, Pandak WM, Dent P, Spiegel S, Shi R, Xu W, Liu X, Bohdan P, Zhang L, Zhou H, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology (Baltimore, Md.). 55: 267-76. PMID 21932398 DOI: 10.1002/hep.24681  0.52
2012 Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Journal of Cellular Physiology. 227: 2145-53. PMID 21780116 DOI: 10.1002/jcp.22947  0.52
2012 Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ, Wang XY, Rizzi F, Bettuzzi S, Lee SG, Dent P, Grant S, Curiel DT, Sarkar D, Fisher PB. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology. 227: 1805-13. PMID 21732348 DOI: 10.1002/jcp.22904  0.52
2011 Senkal CE, Ponnusamy S, Manevich Y, Meyers-Needham M, Saddoughi SA, Mukhopadyay A, Dent P, Bielawski J, Ogretmen B. Alteration of ceramide synthase 6/C16-ceramide induces activating transcription factor 6-mediated endoplasmic reticulum (ER) stress and apoptosis via perturbation of cellular Ca2+ and ER/Golgi membrane network. The Journal of Biological Chemistry. 286: 42446-58. PMID 22013072 DOI: 10.1074/jbc.M111.287383  0.52
2011 Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood. 118: 5189-200. PMID 21911831 DOI: 10.1182/blood-2011-02-339432  0.52
2011 Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opinion On Investigational Drugs. 20: 1397-411. PMID 21851287 DOI: 10.1517/13543784.2011.609167  0.52
2011 Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, Grant S. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. The Journal of Biological Chemistry. 286: 34036-50. PMID 21816815 DOI: 10.1074/jbc.M111.284216  0.52
2011 Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy. 7: 1261-2. PMID 21814046 DOI: 10.4161/auto.7.10.17029  0.52
2011 Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 10: 1686-97. PMID 21750224 DOI: 10.1158/1535-7163.MCT-10-1108  0.52
2011 Dent P, Curiel DT, Fisher PB. The potential of virus-based gene therapies for treatment of metastatic kidney cancer. Expert Review of Anticancer Therapy. 11: 809-11. PMID 21707273 DOI: 10.1586/era.11.59  0.52
2011 Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biology & Therapy. 12: 215-28. PMID 21642769 DOI: 10.4161/cbt.12.3.16218  0.52
2011 Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 71: 4955-67. PMID 21622715 DOI: 10.1158/0008-5472.CAN-11-0898  0.52
2011 Bhutia SK, Das SK, Azab B, Dash R, Su ZZ, Lee SG, Dent P, Curiel DT, Sarkar D, Fisher PB. Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24). Autophagy. 7: 1076-7. PMID 21610321 DOI: 10.4161/auto.7.9.16163  0.52
2011 Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America. 108: 8785-90. PMID 21555592 DOI: 10.1073/pnas.1100769108  0.52
2011 Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Molecular Interventions. 11: 133-40. PMID 21540473 DOI: 10.1124/mi.11.2.11  0.52
2011 Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. British Journal of Haematology. 153: 222-35. PMID 21375523 DOI: 10.1111/j.1365-2141.2011.08591.x  0.52
2011 Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D, Fisher PB. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discovery Medicine. 11: 46-56. PMID 21276410  0.52
2011 Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 117: 1947-57. PMID 21148814 DOI: 10.1182/blood-2010-06-291146  0.52
2011 Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, ... ... Dent P, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.CAN-10-3185  0.52
2011 Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Molecular Pharmacology. 79: 368-80. PMID 21119025 DOI: 10.1124/mol.110.069484  0.52
2010 Eulitt PJ, Park MA, Hossein H, Cruikshanks N, Yang C, Dmitriev IP, Yacoub A, Curiel DT, Fisher PB, Dent P. Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biology & Therapy. 10: 1290-305. PMID 20948318 DOI: 10.4161/cbt.10.12.13497  0.52
2010 Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, ... ... Dent P, et al. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine & Growth Factor Reviews. 21: 381-91. PMID 20926331 DOI: 10.1016/j.cytogfr.2010.08.004  0.52
2010 Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, Dent P, Kukreja RC. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proceedings of the National Academy of Sciences of the United States of America. 107: 18202-7. PMID 20884855 DOI: 10.1073/pnas.1006965107  0.52
2010 Rahmani M, Mayo M, Dash R, Sokhi UK, Dmitriev IP, Sarkar D, Dent P, Curiel DT, Fisher PB, Grant S. Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress. Molecular Pharmacology. 78: 1096-104. PMID 20858700 DOI: 10.1124/mol.110.068007  0.52
2010 Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biology & Therapy. 10: 903-17. PMID 20855960 DOI: 10.4161/cbt.10.9.13273  0.52
2010 Jia W, Loria RM, Park MA, Yacoub A, Dent P, Graf MR. The neuro-steroid, 5-androstene 3β,17α diol; induces endoplasmic reticulum stress and autophagy through PERK/eIF2α signaling in malignant glioma cells and transformed fibroblasts. The International Journal of Biochemistry & Cell Biology. 42: 2019-29. PMID 20851775 DOI: 10.1016/j.biocel.2010.09.003  0.52
2010 Murakami M, Ugai H, Wang M, Belousova N, Dent P, Fisher PB, Glasgow JN, Everts M, Curiel DT. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations. Virology. 407: 196-205. PMID 20828776 DOI: 10.1016/j.virol.2010.08.010  0.52
2010 Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, et al. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacology & Therapeutics. 128: 375-84. PMID 20732354 DOI: 10.1016/j.pharmthera.2010.08.001  0.52
2010 Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology. 151: 70-83. PMID 20701602 DOI: 10.1111/j.1365-2141.2010.08319.x  0.52
2010 Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Molecular Pharmacology. 78: 909-17. PMID 20696794 DOI: 10.1124/mol.110.067199  0.48
2010 Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular Cancer Therapeutics. 9: 2220-31. PMID 20682655 DOI: 10.1158/1535-7163.MCT-10-0274  0.52
2010 Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Research. 70: 6313-24. PMID 20631069 DOI: 10.1158/0008-5472.CAN-10-0999  0.52
2010 Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, et al. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anti-Cancer Drugs. 21: 725-31. PMID 20613485 DOI: 10.1097/CAD.0b013e32833cfbe1  0.52
2010 Dash R, Richards JE, Su ZZ, Bhutia SK, Azab B, Rahmani M, Dasmahapatra G, Yacoub A, Dent P, Dmitriev IP, Curiel DT, Grant S, Pellecchia M, Reed JC, Sarkar D, et al. Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Research. 70: 5034-45. PMID 20501829 DOI: 10.1158/0008-5472.CAN-10-0563  0.52
2010 Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Molecular Cancer Therapeutics. 9: 1378-95. PMID 20442308 DOI: 10.1158/1535-7163.MCT-09-1131  0.52
2010 Bhutia SK, Dash R, Das SK, Azab B, Su ZZ, Lee SG, Grant S, Yacoub A, Dent P, Curiel DT, Sarkar D, Fisher PB. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Research. 70: 3667-76. PMID 20406981 DOI: 10.1158/0008-5472.CAN-09-3647  0.52
2010 Cao R, Cronk ZX, Zha W, Sun L, Wang X, Fang Y, Studer E, Zhou H, Pandak WM, Dent P, Gil G, Hylemon PB. Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway. Journal of Lipid Research. 51: 2234-44. PMID 20305288 DOI: 10.1194/jlr.M004929  0.52
2010 Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 115: 4478-87. PMID 20233973 DOI: 10.1182/blood-2009-12-257261  0.52
2010 Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1130-42. PMID 20179672 DOI: 10.1038/mt.2010.29  0.52
2010 Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research. 34: 379-86. PMID 20117835 DOI: 10.1016/j.leukres.2009.07.013  0.52
2010 Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitrie IP, Chen CS, Grant S, Curiel DT, Fisher PB, Dent P. OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biology & Therapy. 9: 526-36. PMID 20107314  0.52
2010 Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, Grant S, Curiel DT, Fisher PB, Dent P. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Research. 70: 1120-9. PMID 20103619 DOI: 10.1158/0008-5472.CAN-09-4043  0.52
2010 Oyesanya RA, Greenbaum S, Dang D, Lee Z, Mukherjee A, Wu J, Dent P, Fang X. Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid. Molecular Cancer. 9: 8. PMID 20074357 DOI: 10.1186/1476-4598-9-8  0.52
2010 Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 285: 10064-77. PMID 20065354 DOI: 10.1074/jbc.M109.095208  0.52
2010 Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK, Dash R, Yacoub A, Fuller CE, Shah K, Dent P, Bruce JN, Fisher PB. Astrocyte elevated gene-1: a novel target for human glioma therapy. Molecular Cancer Therapeutics. 9: 79-88. PMID 20053777 DOI: 10.1158/1535-7163.MCT-09-0752  0.52
2010 Sauane M, Su ZZ, Dash R, Liu X, Norris JS, Sarkar D, Lee SG, Allegood JC, Dent P, Spiegel S, Fisher PB. Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis. Journal of Cellular Physiology. 222: 546-55. PMID 19937735 DOI: 10.1002/jcp.21969  0.52
2010 Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, Sarkar D, Dimitriev IP, Bell JK, Grant S, Farrell NP, Curiel DT, Fisher PB, Dent P. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Molecular Pharmacology. 77: 298-310. PMID 19910452 DOI: 10.1124/mol.109.061820  0.52
2010 Murakami M, Ugai H, Belousova N, Pereboev A, Dent P, Fisher PB, Everts M, Curiel DT. Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells. The Prostate. 70: 362-76. PMID 19902467 DOI: 10.1002/pros.21070  0.52
2010 Greco A, Di Benedetto A, Howard CM, Kelly S, Nande R, Dementieva Y, Miranda M, Brunetti A, Salvatore M, Claudio L, Sarkar D, Dent P, Curiel DT, Fisher PB, Claudio PP. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 295-306. PMID 19888195 DOI: 10.1038/mt.2009.252  0.52
2009 Dent P, Curiel DT, Grant S, Fisher PB. Minting a new class of polo-like-kinase inhibitors. Cancer Biology & Therapy. 8: 2384-5. PMID 20009506  0.52
2009 Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biology & Therapy. 8: 2084-96. PMID 19823038  0.52
2009 Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood. 114: 4507-16. PMID 19773546 DOI: 10.1182/blood-2008-09-177881  0.52
2009 Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Research. 69: 6915-23. PMID 19723667 DOI: 10.1158/0008-5472.CAN-09-0664  0.52
2009 Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular Pharmacology. 76: 327-41. PMID 19483105 DOI: 10.1124/mol.109.056309  0.52
2009 Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Molecular Pharmacology. 76: 342-55. PMID 19483104 DOI: 10.1124/mol.109.056523  0.52
2009 Chen L, Jarujaron S, Wu X, Sun L, Zha W, Liang G, Wang X, Gurley EC, Studer EJ, Hylemon PB, Pandak WM, Zhang L, Wang G, Li X, Dent P, et al. HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages. Biochemical Pharmacology. 78: 70-7. PMID 19447225 DOI: 10.1016/j.bcp.2009.03.022  0.52
2009 Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, ... ... Dent P, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Molecular Cancer Therapeutics. 8: 1280-91. PMID 19417161 DOI: 10.1158/1535-7163.MCT-09-0073  0.52
2009 Dent P, Curiel DT, Fisher PB, Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 65-73. PMID 19395305 DOI: 10.1016/j.drup.2009.03.001  0.52
2009 Graf MR, Jia W, Johnson RS, Dent P, Mitchell C, Loria RM. Autophagy and the functional roles of Atg5 and beclin-1 in the anti-tumor effects of 3beta androstene 17alpha diol neuro-steroid on malignant glioma cells. The Journal of Steroid Biochemistry and Molecular Biology. 115: 137-45. PMID 19375507 DOI: 10.1016/j.jsbmb.2009.03.013  0.52
2009 Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. Journal of Lipid Research. 50: 1509-20. PMID 19346331 DOI: 10.1194/jlr.R900007-JLR200  0.52
2009 Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, Fisher PB. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biology & Therapy. 8: 391-400. PMID 19276652  0.52
2009 Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology & Therapy. 8: 808-19. PMID 19270531  0.52
2009 Van Maerken T, Sarkar D, Speleman F, Dent P, Weiss WA, Fisher PB. Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma. Journal of Cellular Physiology. 219: 707-15. PMID 19202553 DOI: 10.1002/jcp.21719  0.52
2009 Dent P, Grant S, Fisher PB, Curiel DT. PI3K: A rational target for ovarian cancer therapy? Cancer Biology & Therapy. 8: 27-30. PMID 19127116  0.52
2009 Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Research. 69: 143-50. PMID 19117997 DOI: 10.1158/0008-5472.CAN-07-6656  0.52
2008 Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Molecular Cancer Therapeutics. 7: 2633-48. PMID 18790746 DOI: 10.1158/1535-7163.MCT-08-0400  0.52
2008 Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology & Therapy. 7: 1648-62. PMID 18787411  0.52
2008 Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5385-99. PMID 18765530 DOI: 10.1158/1078-0432.CCR-08-0469  0.52
2008 Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 283: 24343-58. PMID 18614532 DOI: 10.1074/jbc.M803444200  0.52
2008 Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Molecular Pharmacology. 74: 807-22. PMID 18544666 DOI: 10.1124/mol.108.047365  0.52
2008 Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, Yacoub A, Hagan MP, Dent P. Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology & Therapy. 7: 587-93. PMID 18379195  0.52
2008 Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Molecular Cancer Therapeutics. 7: 616-29. PMID 18347148 DOI: 10.1158/1535-7163.MCT-07-2376  0.52
2008 Sarkar D, Dent P, Curiel DT, Fisher PB. Acquired and innate resistance to the cancer-specific apoptosis-inducing cytokine, mda-7/IL-24: Not insurmountable therapeutic problems Cancer Biology and Therapy. 7: 109-112. PMID 18277093  0.52
2008 Sarkar D, Dent P, Curiel DT, Fisher PB. INGN-241: Cancer gene therapy Drugs of the Future. 33: 396-401. DOI: 10.1358/dof.2008.033.05.1201624  0.52
2007 Dent P, Hylemon PB, Grant S, Fisher PB. Approaches for monitoring signal transduction changes in normal and cancer cells Methods in Molecular Biology (Clifton, N.J.). 383: 259-276. PMID 18217691  0.52
2007 Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Molecular Cancer Therapeutics. 6: 3101-12. PMID 18065490 DOI: 10.1158/1535-7163.MCT-07-0561  0.52
2007 Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation Clinical Cancer Research. 13: 4280-4290. PMID 17634558 DOI: 10.1158/1078-0432.CCR-07-0835  0.52
2007 Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Molecular Pharmacology. 72: 788-95. PMID 17595328 DOI: 10.1124/mol.106.033308  0.52
2007 Grant S, Dent P. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: Implications for new approaches to the treatment of childhood leukemias Current Drug Targets. 8: 751-759. PMID 17584030 DOI: 10.2174/138945007780830764  0.52
2007 Mitchell C, Kabolizadeh P, Ryan J, Roberts JD, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Molecular Pharmacology. 72: 704-14. PMID 17578896 DOI: 10.1124/mol.107.038406  0.52
2007 Mitchell C, Park MA, Zhang G, Han SI, Harada H, Franklin RA, Yacoub A, Li PL, Hylemon PB, Grant S, Dent P. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Molecular Cancer Therapeutics. 6: 618-32. PMID 17308059 DOI: 10.1158/1535-7163.MCT-06-0532  0.52
2007 Hagan MP, Yacoub A, Dent P. Radiation-induced PARP activation is enhanced through EGFR-ERK signaling. Journal of Cellular Biochemistry. 101: 1384-93. PMID 17295209 DOI: 10.1002/jcb.21253  0.52
2007 Fang Y, Studer E, Mitchell C, Grant S, Pandak WM, Hylemon PB, Dent P. Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling. Molecular Pharmacology. 71: 1122-8. PMID 17200418 DOI: 10.1124/mol.106.032060  0.52
2006 Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Molecular Pharmacology. 70: 589-603. PMID 16622074 DOI: 10.1124/mol.106.025007  0.52
2006 Dasmahapatra G, Nguyen TK, Dent P, Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leukemia Research. 30: 1263-72. PMID 16481037 DOI: 10.1016/j.leukres.2006.01.005  0.52
2006 Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry Cell Cycle. 5: 437-446. PMID 16479154  0.52
2006 Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism Blood. 107: 232-240. PMID 16166589 DOI: 10.1182/blood-2005-06-2302  0.52
2006 Sarkar D, Dent P, Fisher PB. Melanoma differentiation associated gene-7 (mda-7)/ interleukin-24 (IL-24), mda-7/IL-24: Current perspectives on a unique member of the IL-10 family of cytokines Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry. 5: 259-274. DOI: 10.2174/187152306778017719  0.52
2005 Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biology & Therapy. 4: 1275-84. PMID 16319524  0.52
2005 Dent P, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Hylemon PB. Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology (Baltimore, Md.). 42: 1291-9. PMID 16317705 DOI: 10.1002/hep.20942  0.52
2005 Qiao L, Yu J, Dent P, Farrell G. NF-κB protects rat ARL-6 hepatocellular carcinoma cells against hydrogen peroxide-induced apoptosis Cancer Biology and Therapy. 4: 1195-1202. PMID 16177566  0.52
2005 Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells Leukemia. 19: 1579-1589. PMID 16015388 DOI: 10.1038/sj.leu.2403868  0.52
2005 Dent P, Yacoub A, Grant S. DMC: Novel celecoxib derivatives to rap cancer Cancer Biology and Therapy. 4: 583-584. PMID 15970676  0.52
2005 Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation Molecular and Cellular Biology. 25: 5429-5444. PMID 15964800 DOI: 10.1128/MCB.25.13.5429-5444.2005  0.52
2005 Dent P, Yacoub A, Grant S, Curiel DT, Fisher PB. MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy? Journal of Cellular Biochemistry. 95: 712-719. PMID 15880678 DOI: 10.1002/jcb.20502  0.52
2005 Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process Oncogene. 24: 3797-3809. PMID 15782127 DOI: 10.1038/sj.onc.1208530  0.52
2005 Shore SM, Byers SA, Dent P, Price DH. Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. Gene. 350: 51-8. PMID 15780980 DOI: 10.1016/j.gene.2005.01.015  0.52
2004 Dent P, Grant S. Irofulven: Resurgence for alkylating therapy in cancer? Cancer Biology and Therapy. 3: 1143-1144. PMID 15640616  0.52
2004 Ahmed W, Rahmani M, Dent P, Grant S. The cyclin-dependent kinase inhibitor p21CIP1/WAF1 blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells Cell Cycle. 3: 1305-1311. PMID 15467449  0.52
2004 Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5724-31. PMID 15355899 DOI: 10.1158/1078-0432.CCR-04-0420  0.52
2004 Grant S, Dent P. Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name? Molecular Cancer Therapeutics. 3: 873-875. PMID 15252148  0.52
2004 Grant S, Dent P. Activation of MAP kinase pathways by TRAIL: Don't expect the obvious Cancer Biology and Therapy. 3: 302-304. PMID 15107606  0.52
2004 Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib Experimental Cell Research. 295: 555-566. PMID 15093752 DOI: 10.1016/j.yexcr.2004.02.001  0.52
2004 Grant S, Dent P. Kinase Inhibitors and Cytotoxic Drug Resistance Clinical Cancer Research. 10: 2205-2207. PMID 15073093 DOI: 10.1158/1078-0432.CCR-0001-4  0.52
2003 Dai Y, Dent P, Grant S. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL Molecular Pharmacology. 64: 1402-1409. PMID 14645670 DOI: 10.1124/mol.64.6.1402  0.52
2003 Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene. 22: 5885-96. PMID 12947395 DOI: 10.1038/sj.onc.1206701  0.52
2003 Wang S, Wang Z, Dent P, Grant S. Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells. Blood. 101: 3648-57. PMID 12522001 DOI: 10.1182/blood-2002-09-2739  0.52
2002 Yu C, Dai Y, Dent P, Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to STI571 Cancer Biology and Therapy. 1: 674-682. PMID 12642693  0.52
2002 Grant S, Dent P. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors Cell Cycle (Georgetown, Tex.). 1: 383-388. PMID 12548009  0.52
2002 Dent P. Ribonucleotide reductase inhibition: regulation of the radiosensitive phenotype via NF kappa B and Bcl-2 Cancer Biology &Amp; Therapy. 1: 546-547. PMID 12496486  0.52
2002 Grant S, Fisher PB, Dent P. The role of signal transduction pathways in drug and radiation resistance Cancer Treatment and Research. 112: 89-108. PMID 12481713  0.52
2002 Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A Cell Cycle (Georgetown, Tex.). 1: 143-152. PMID 12429924  0.52
2002 Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells Clinical Cancer Research. 8: 2976-2984. PMID 12231544  0.52
2002 Su ZZ, Gopalkrishnan RV, Narayan G, Dent P, Fisher PB. Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells. Journal of Cellular Physiology. 192: 34-44. PMID 12115734 DOI: 10.1002/jcp.10114  0.52
2002 Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival Frontiers in Bioscience : a Journal and Virtual Library. 7. PMID 11815285  0.52
2002 Dent P. Ribonucleotide reductase inhibition: Regulation of the radiosensitive phenotype via NFkB and Bcl-2 Cancer Biology and Therapy. 1: 527-528. DOI: 10.4161/cbt.1.5.175  0.52
2001 Grant S, Dent P. Overview: Rational integration of agents directed at novel therapeutic targets into combination chemotherapeutic regimens Current Opinion in Investigational Drugs. 2: 1600-1605. PMID 11763164  0.52
2001 Yacoub A, Park JS, Qiao L, Dent P, Hagan MP. MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. International Journal of Radiation Biology. 77: 1067-78. PMID 11682011 DOI: 10.1080/09553000110069317  0.52
2001 Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacology & Therapeutics. 90: 105-56. PMID 11578655 DOI: 10.1016/S0163-7258(01)00132-2  0.52
2001 Yu C, Wang Z, Dent P, Grant S. MEK1/2 inhibitors promote ara-C-induced apoptosis but not loss of δψm HL-60 cells Biochemical and Biophysical Research Communications. 286: 1011-1018. PMID 11527401 DOI: 10.1006/bbrc.2001.5513  0.52
2001 Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Molecular Pharmacology. 60: 143-54. PMID 11408609  0.52
2001 Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: Potential role in promoting cytotoxic drug action Clinical Cancer Research. 7: 775-783. PMID 11309321  0.52
2001 Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of Cholesterol 7α-Hydroxylase (CYP7A1) Gene Expression by Bile Acids in Primary Rat Hepatocytes is Mediated by the c-Jun N-terminal Kinase Pathway Journal of Biological Chemistry. 276: 15816-15822. PMID 11278771 DOI: 10.1074/jbc.M010878200  0.52
2000 Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-β-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) Biochemical Pharmacology. 60: 1445-1456. PMID 11020446 DOI: 10.1016/S0006-2952(00)00463-9  0.52
2000 Wang Z, Wang S, Fisher PB, Dent P, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. Differentiation; Research in Biological Diversity. 66: 1-13. PMID 10997587 DOI: 10.1046/j.1432-0436.2000.066001001.x  0.52
2000 Madireddi MT, Dent P, Fisher PB. AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation. Journal of Cellular Physiology. 185: 36-46. PMID 10942517 DOI: 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V  0.52
2000 Bondzi C, Litz J, Dent P, Krystal GW. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 305-14. PMID 10910097  0.52
2000 Madireddi MT, Dent P, Fisher PB. Regulation of mda-7 gene expression during human melanoma differentiation. Oncogene. 19: 1362-8. PMID 10713678 DOI: 10.1038/sj.onc.1203424  0.52
1999 Taher MM, Baumgardner T, Dent P, Valerie K. Genetic evidence that stress-activated p38 MAP kinase is necessary but not sufficient for UV activation of HIV gene expression Biochemistry. 38: 13055-13062. PMID 10529175 DOI: 10.1021/bi9902900  0.52
1999 Vrana JA, Grant S, Dent P. Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation Radiation Research. 151: 559-569. PMID 10319729 DOI: 10.2307/3580032  0.52
1999 Smith RD, Baukal AJ, Dent P, Catt KJ. Raf-1 kinase activation by angiotensin II in adrenal glomerulosa cells: roles of Gi, phosphatidylinositol 3-kinase, and Ca2+ influx. Endocrinology. 140: 1385-91. PMID 10067866 DOI: 10.1210/endo.140.3.6600  0.52
1996 Jelinek T, Dent P, Sturgill TW, Weber MJ. Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation Molecular and Cellular Biology. 16: 1027-1034. PMID 8622647  0.52
1995 Dent P, Romero G, Castle D, Sturgill TW. Preparation and use of semiintact mammalian cells for analysis of signal transduction Methods in Enzymology. 255: 265-273. PMID 8524110 DOI: 10.1016/S0076-6879(95)55029-1  0.52
1995 Dent P, Reardon DB, Morrison DK, Sturgill TW. Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras- independent mechanisms in vitro Molecular and Cellular Biology. 15: 4125-4135. PMID 7623807  0.52
1994 Rossomando AJ, Dent P, Sturgill TW, Marshak DR. Mitogen-activated protein kinase kinase 1 (MKK1) is negatively regulated by threonine phosphorylation Molecular and Cellular Biology. 14: 1594-1602. PMID 8114697  0.52
1994 Dent P, Sturgill TW. Activation of (His)6-Raf-1 in vitro by partially purified plasma membranes from v-Ras-transformed and serum-stimulated fibroblasts Proceedings of the National Academy of Sciences of the United States of America. 91: 9544-9548. PMID 7937802  0.52
1992 Dent P, MacDougall LK, Mackintosh C, Campbell DG, Cohen P. A myofibrillar protein phosphatase from rabbit skeletal muscle contains the β isoform of protein phosphatase-1 complexed to a regulatory subunit which greatly enhances the dephosphorylation of myosin European Journal of Biochemistry. 210: 1037-1044. PMID 1336456 DOI: 10.1111/j.1432-1033.1992.tb17509.x  0.52
1990 Hubbard MJ, Dent P, Smythe C, Cohen P. Targetting of protein phosphatase 1 to the sarcoplasmic reticulum of rabbit skeletal muscle by a protein that is very similar or identical to the G subunit that directs the enzyme to glycogen European Journal of Biochemistry. 189: 243-249. PMID 2159875  0.52
1990 Dent P, Campbell DG, Caudwell FB, Cohen P. Identification of three in vivo phosphorylation sites on the glycogen-binding subunit of protein phosphatase 1 from rabbit skeletal muscle, and their response to adrenaline Febs Letters. 259: 281-285. PMID 2152882 DOI: 10.1016/0014-5793(90)80027-G  0.52
1989 Dent P, Campbell DG, Hubbard MJ, Cohen P. Multisite phosphorylation of the glycogen-binding subunit of protein phosphatase-1G by cyclic AMP-dependent protein kinase and glycogen synthase kinase-3 Febs Letters. 248: 67-72. PMID 2542090 DOI: 10.1016/0014-5793(89)80433-8  0.52
Show low-probability matches.